At Crofoot MD, we are committed to advancing medical knowledge and improving patient outcomes through innovative clinical research. Our current studies focus on groundbreaking treatments for HIV, RSV, and COVID-19, with an emphasis on diverse and underrepresented populations. These studies include evaluating new therapies like the weekly Islatravir/Lenacapavir regimen for HIV treatment and exploring promising options for COVID-19 and RSV management.

A study funded by the National Cancer Institute explored if sexual minority men and transgender women could self-detect anal abnormalities earlier than usual cancer diagnoses. Among 714 participants, clinicians found abnormalities in 34.3% of cases, with a median lesion size of just 3 mm. Self-examinations (ASE/ACE) had 59.6% sensitivity and 80.2% specificity, showing promise for earlier detection of squamous cell carcinoma of the anus (SCCA).

Islatravir (ISL), a nucleoside reverse transcriptase translocation inhibitor, and lenacapavir (LEN), a capsid inhibitor, have potent anti-HIV-1 activity and pharmacokinetic profiles permitting once-weekly (QW) oral dosing. We investigated efficacy and safety of ISL+LEN in virologically suppressed people with HIV-1.

Long-acting treatment for HIV has potential to improve adherence, provide durable viral suppression, and have long-term individual and public health benefits. We evaluated treatment with two antibodies that broadly and potently neutralise HIV (broadly neutralising antibodies; bNAbs), combined with lenacapavir, a long-acting capsid inhibitor, as a long-acting regimen.

Data characterising the long-term use and safety of emtricitabine plus tenofovir disoproxil fumarate as daily oral pre-exposure prophylaxis (PrEP) are scarce and there are uncertainties regarding the value of routine HIV-1 RNA testing during oral PrEP follow-up.